Marshall Gerstein recognizes the increasing disruptions, anxiety, and suffering caused by COVID-19. Our deepest sympathy and thoughts of peace and courage go out to all who have been personally affected around the world.
Our firm is committed to observing best practices to protect the health of our employees and to ensure uninterrupted service to our clients.
Please click here for more details.
Our blog covering post-grant proceedings at the USPTOGo to PTABWatch
Through the rise of biosimilars, the evolution of patent eligibility, and the advent of hedge-fund challenges to pharma patents, Marshall Gerstein keeps a watchful eye on biotechnology and life sciences PTAB developments.Go to Eye on Biotech